228. 閉塞性細気管支炎 Bronchiolitis obliterans Clinical trials / Disease details
臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00141726 (ClinicalTrials.gov) | October 2003 | 30/8/2005 | Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant | Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study | Lung Injury, Acute;Respiratory Distress Syndrome, Adult;Bronchiolitis Obliterans | Drug: Etanercept | University of Michigan Cancer Center | NULL | Completed | 6 Years | N/A | All | 34 | Phase 2 | United States |
2 | NCT00029328 (ClinicalTrials.gov) | September 2001 | 10/1/2002 | Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation | Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation | Respiratory Distress Syndrome, Adult;Bronchiolitis Obliterans;Pneumonia | Drug: etanercept | FDA Office of Orphan Products Development | NULL | Completed | 12 Months | N/A | Both | 15 | Phase 1/Phase 2 | United States |